Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9130)
All Articles published online
|
Publishing Process of This Article
|
Jun 21, 2014 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7356-7365 [PMID: 24966606 DOI: 10.3748/wjg.v20.i23.7356] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i23/7356.htm |
| Number | Citing Articles |
| 1 |
Günaj Rakipovski, Bidda Rolin, Jane Nøhr, Ib Klewe, Klaus S. Frederiksen, Robert Augustin, Jacob Hecksher-Sørensen, Camilla Ingvorsen, Joseph Polex-Wolf, Lotte Bjerre Knudsen. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways. JACC: Basic to Translational Science 2018; 3(6): 844 doi: 10.1016/j.jacbts.2018.09.004
|
| 2 |
Bilal A. Omar, Bo Ahrén. Extrapancreatic contribution to glucose regulation by dipeptidyl peptidase 4 inhibition. Cardiovascular Endocrinology 2016; 5(3): 82 doi: 10.1097/XCE.0000000000000088
|
| 3 |
Seung Hee Choi, Jaechan Leem, In-Kyu Lee. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice. Mediators of Inflammation 2017; 2017: 1 doi: 10.1155/2017/4139439
|
| 4 |
Yousaf Zafar, Ahmed Mustafa Rashid, Ahmed Kamal Siddiqi, Aayat Ellahi, Aymen Ahmed, Hassan ul Hussain, Furqan Ahmed, Ritesh G. Menezes, Tariq Jamal Siddiqi, Muhammad Talha Maniya. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2022; 46(7): 101970 doi: 10.1016/j.clinre.2022.101970
|
| 5 |
André J. Scheen. Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 2014; 53(9): 773 doi: 10.1007/s40262-014-0157-y
|
| 6 |
Jose A. Gimeno-Orna, Guayente Verdes-Sanz, Laura Borau-Maorad, Julia Campos-Fernández, Beatriz Lardiés-Sánchez, Marta Monreal-Villanueva. Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists. Endocrinología y Nutrición (English Edition) 2016; 63(4): 164 doi: 10.1016/j.endoen.2016.04.005
|
| 7 |
M. M. Smits, L. Tonneijck, M. H. A. Muskiet, M. H. H. Kramer, D. L. Cahen, D. H. van Raalte. Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas. Diabetes, Obesity and Metabolism 2016; 18(3): 224 doi: 10.1111/dom.12593
|
| 8 |
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8): 1109 doi: 10.1016/j.metabol.2016.05.003
|
| 9 |
Mei-Yueh Lee, Wei-Chun Chen, Wei-Hao Hsu, Szu-Chia Chen, Jin-Ching Lee. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism. International Journal of Molecular Sciences 2019; 20(18): 4569 doi: 10.3390/ijms20184569
|
| 10 |
Hui Chen, Ting Cao, Bikui Zhang, Hualin Cai. The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1097284
|
| 11 |
Christian Baumeier, Sophie Saussenthaler, Anne Kammel, Markus Jähnert, Luisa Schlüter, Deike Hesse, Mickaël Canouil, Stephane Lobbens, Robert Caiazzo, Violeta Raverdy, François Pattou, Emma Nilsson, Jussi Pihlajamäki, Charlotte Ling, Philippe Froguel, Annette Schürmann, Robert W. Schwenk. Hepatic DPP4 DNA Methylation Associates With Fatty Liver. Diabetes 2017; 66(1): 25 doi: 10.2337/db15-1716
|
| 12 |
Nwe Ni Than, Philip N. Newsome. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015; 239(1): 192 doi: 10.1016/j.atherosclerosis.2015.01.001
|
| 13 |
Dinali H. Fernando, Josephine M. Forbes, Peter W. Angus, Chandana B. Herath. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. International Journal of Molecular Sciences 2019; 20(20): 5037 doi: 10.3390/ijms20205037
|
| 14 |
Rehab F. Abdel-Rahman. Non-alcoholic fatty liver disease. Asian Pacific Journal of Tropical Biomedicine 2022; 12(3): 99 doi: 10.4103/2221-1691.338919
|
| 15 |
Megumi Shiomi, Yoichi Tanaka, Tesshu Takada, Katsuya Otori. Determining whether the effect of liraglutide on non‐alcoholic fatty liver disease depends on reductions in the body mass index. JGH Open 2020; 4(5): 995 doi: 10.1002/jgh3.12384
|
| 16 |
Laura J Carbone, Peter W Angus, Neville D Yeomans. Incretin‐based therapies for the treatment of non‐alcoholic fatty liver disease: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2016; 31(1): 23 doi: 10.1111/jgh.13026
|
| 17 |
Eduardo García Díaz, Danila Guagnozzi, Verónica Gutiérrez, Carmen Mendoza, Cristina Maza, Yulene Larrañaga, Dolores Perdomo, Teresa Godoy, Ghalli Taleb. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. Endocrinología y Nutrición (English Edition) 2016; 63(5): 194 doi: 10.1016/j.endoen.2016.05.008
|
| 18 |
Maria Kalogirou, Emmanouil Sinakos. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?. World Journal of Hepatology 2018; 10(11): 790-794 doi: 10.4254/wjh.v10.i11.790
|
| 19 |
Jose A. Gimeno-Orna, Guayente Verdes-Sanz, Laura Borau-Maorad, Julia Campos-Fernández, Beatriz Lardiés-Sánchez, Marta Monreal-Villanueva. Niveles de ALT y respuesta hipoglucemiante al tratamiento con agonistas del receptor de GLP-1. Endocrinología y Nutrición 2016; 63(4): 164 doi: 10.1016/j.endonu.2015.11.009
|
| 20 |
Ides M. Colin, Henri Colin, Ines Dufour, Charles‐Edouard Gielen, Marie‐Christine Many, Jean Saey, Bernard Knoops, Anne‐Catherine Gérard. Extrapancreatic effects of incretin hormones: evidence for weight‐independent changes in morphological aspects and oxidative status in insulin‐sensitive organs of the obese nondiabetic Zucker rat (ZFR). Physiological Reports 2016; 4(15) doi: 10.14814/phy2.12886
|
| 21 |
Eduardo García Díaz, Danila Guagnozzi, Verónica Gutiérrez, Carmen Mendoza, Cristina Maza, Yulene Larrañaga, Dolores Perdomo, Teresa Godoy, Ghalli Taleb. Efecto de las terapias incretínicas comparadas con pioglitazona y gliclazida en la esteatosis hepática no alcohólica de los pacientes diabéticos no controlados solo con metformina: estudio observacional piloto. Endocrinología y Nutrición 2016; 63(5): 194 doi: 10.1016/j.endonu.2016.01.006
|
| 22 |
Takayasu Ideta, Yohei Shirakami, Tsuneyuki Miyazaki, Takahiro Kochi, Hiroyasu Sakai, Hisataka Moriwaki, Masahito Shimizu. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. International Journal of Molecular Sciences 2015; 16(12): 29207 doi: 10.3390/ijms161226156
|
| 23 |
Eunüs S. Ali, Jin Hua, Claire H. Wilson, George A. Tallis, Fiona H. Zhou, Grigori Y. Rychkov, Greg J. Barritt. The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca 2+ signalling in steatotic hepatocytes. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2016; 1863(9): 2135 doi: 10.1016/j.bbamcr.2016.05.006
|
| 24 |
Noriyuki Kaji, Yoshiichi Takagi, Satomi Matsuda, Anna Takahashi, Sakurako Fujio, Fumitoshi Asai. Effects of liraglutide on metabolic syndrome in WBN/Kob diabetic fatty rats supplemented with a high‐fat diet. Animal Models and Experimental Medicine 2020; 3(1): 62 doi: 10.1002/ame2.12106
|
| 25 |
Ines Bilic Curcic, Maja Cigrovski Berkovic, Lucija Kuna, Hrvoje Roguljic, Robert Smolic, Silvija Canecki Varzic, Lucija Virovic Jukic, Martina Smolic. Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing?. Journal of Clinical and Translational Hepatology 2019; 7(3): 1 doi: 10.14218/JCTH.2019.00029
|
| 26 |
Tian Shen, Bilin Xu, Tao Lei, Lin Chen, Cuiping Zhang, Zhenhua Ni. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6554
|
| 27 |
Zuo-Di Fu, Xiao-Ling Cai, Wen-Jia Yang, Ming-Ming Zhao, Ran Li, Yu-Feng Li. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World Journal of Diabetes 2021; 12(1): 84-97 doi: 10.4239/wjd.v12.i1.84
|
| 28 |
Sara Salehi Hammerstad, Shira Frankel Grock, Hanna J. Lee, Alia Hasham, Nina Sundaram, Yaron Tomer. Diabetes and Hepatitis C: A Two-Way Association. Frontiers in Endocrinology 2015; 6 doi: 10.3389/fendo.2015.00134
|